open access

Vol 92, No 1 (2021)
Review paper
Published online: 2021-01-29
Get Citation

Metformin administration during pregnancy — current insight

Milena Skibinska12, Monika Zurawska- Klis2, Michal Krekora1, Katarzyna Cypryk2
DOI: 10.5603/GP.a2020.0149
·
Pubmed: 33576490
·
Ginekol Pol 2021;92(1):46-50.
Affiliations
  1. Department of Obstetrics and Gynecology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland
  2. Department of Internal Diseases and Diabetology, Central Clinical Hospital of The Medical University, Lodz, Poland, Poland

open access

Vol 92, No 1 (2021)
REVIEW PAPERS Obstetrics
Published online: 2021-01-29

Abstract

The main mechanism of gestational diabetes mellitus (GDM) is insulin resistance, therefore using metformin as a medicine
reducing insulin resistance appears to be promising.
Currently, the majority of medical associations do not recommend using metformin during pregnancy as the first-line of
therapy when the diet regimen is insufficient for glycaemic control. However, they do allow its administration if there is
no possibility of insulin treatment.
There is some evidence which suggests that using metformin during pregnancy is not related to an increased risk of obstetric
complications during delivery and that its influence on the foetus can be beneficial.
Since metformin crosses the placenta, the major argument for cautious use of this drug are the potential long-term effects
of the treatment for the child and its development in later life.
In this article, the authors attempt to discuss the use of metformin during pregnancy and the safety of the treatment in
the light of current studies and recommendations.

Abstract

The main mechanism of gestational diabetes mellitus (GDM) is insulin resistance, therefore using metformin as a medicine
reducing insulin resistance appears to be promising.
Currently, the majority of medical associations do not recommend using metformin during pregnancy as the first-line of
therapy when the diet regimen is insufficient for glycaemic control. However, they do allow its administration if there is
no possibility of insulin treatment.
There is some evidence which suggests that using metformin during pregnancy is not related to an increased risk of obstetric
complications during delivery and that its influence on the foetus can be beneficial.
Since metformin crosses the placenta, the major argument for cautious use of this drug are the potential long-term effects
of the treatment for the child and its development in later life.
In this article, the authors attempt to discuss the use of metformin during pregnancy and the safety of the treatment in
the light of current studies and recommendations.

Get Citation

Keywords

metformin; pregnancy; diabetes mellitus; GDM

About this article
Title

Metformin administration during pregnancy — current insight

Journal

Ginekologia Polska

Issue

Vol 92, No 1 (2021)

Article type

Review paper

Pages

46-50

Published online

2021-01-29

DOI

10.5603/GP.a2020.0149

Pubmed

33576490

Bibliographic record

Ginekol Pol 2021;92(1):46-50.

Keywords

metformin
pregnancy
diabetes mellitus
GDM

Authors

Milena Skibinska
Monika Zurawska- Klis
Michal Krekora
Katarzyna Cypryk

References (35)
  1. Catalano PM, Kirwan JP, Haugel-de Mouzon S, et al. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr. 2003; 133(5 Suppl 2): 1674S–1683S.
  2. Romero R, Erez O, Hüttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017; 217(3): 282–302.
  3. Garcia-Contreras C, Vazquez-Gomez M, Pesantez-Pacheco JL, et al. Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses. Biomolecules. 2019; 9(5).
  4. Hague WM, Davoran PH, McIntyre D, et al. Metformin crosses the placenta: a modulator for fetal insulin resistance. BMJ. 2003; 327: 880–881.
  5. Lindsay RS, Loeken MR. Metformin use in pregnancy: promises and uncertainties. Diabetologia. 2017; 60(9): 1612–1619.
  6. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006(1): CD002967.
  7. American Diabetes Association. 14. Management of Diabetes in Pregnancy: . Diabetes Care. 2019; 42(Suppl 1): S165–S172.
  8. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010; 95(12): E448–E455.
  9. Hellmuth E, Damm P, Mølsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000; 17(7): 507–511.
  10. Hughes RCE, Rowan JA. Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? Diabet Med. 2006; 23(3): 318–322.
  11. Feig DS, Murphy K, Asztalos E, et al. MiTy Collaborative Group. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. BMC Pregnancy Childbirth. 2016; 16(1): 173.
  12. Lee HY, Wei D, Loeken MR. Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy. Diabetes Metab Res Rev. 2014; 30(1): 23–30.
  13. Cassina M, Donà M, Di Gianantonio E, et al. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014; 20(5): 656–669.
  14. Wang R, Kim BV, van Wely M, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017; 356: j138.
  15. Singh AK, Singh R. Metformin in gestational diabetes: An emerging contender. Indian J Endocrinol Metab. 2015; 19(2): 236–244.
  16. Rowan JA, Hague WM, Gao W, et al. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008; 358(19): 2003–2015.
  17. Farrar D, Simmonds M, Bryant M, et al. Treatments for gestational diabetes: a systematic review and meta-analysis. BMJ Open. 2017; 7(6): e015557.
  18. Rowan JA, Rush EC, Obolonkin V, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011; 34(10): 2279–2284.
  19. Battin MR, Obolonkin V, Rush E, et al. Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial. BMC Pediatr. 2015; 15: 54.
  20. Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care. 2018; 6(1): e000456.
  21. Ijäs H, Vääräsmäki M, Saarela T, et al. A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. BJOG. 2015; 122(7): 994–1000.
  22. van Weelden W, Wekker V, de Wit L, et al. Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs. Diabetes Ther. 2018; 9(5): 1811–1829.
  23. Hanem LG, Salvesen Ø, Juliusson PB, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019; 3(3): 166–174.
  24. Butalia S, Gutierrez L, Lodha A, et al. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med. 2017; 34(1): 27–36.
  25. Wouldes TA, Battin M, Coat S, et al. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed. 2016; 101(6): F488–F493.
  26. Landi SN, Radke S, Engel SM, et al. Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA Pediatr. 2019; 173(2): 160–168.
  27. http://www.whqlibdoc.who.int/publications/2006/924159084X_eng.pdf?ua=1.
  28. http://www.idf.org/webdata/docs/Pregnancy_EN_RTP.pdf.
  29. Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018; 131(2): e49–e64.
  30. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline 2015.
  31. Society of Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org. SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018; 218(5): B2–B4.
  32. Barbour LA, Scifres C, Valent AM, et al. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018; 219(4): 367.e1–367.e7.
  33. Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015; 131 Suppl 3: S173–S211.
  34. Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2019. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabeto lPrakt. 2019; 5(1): 65–68.
  35. Wender-Ożegowska E, Bomba-Opoń D, Brązert J, et al. Standards of Polish Society of Gynecologists and Obstetricians in management of women with diabetes. Ginekol Pol. 2018; 89(6): 341–350.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl